Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases

Ekaterina Dadachova, Arturo Casadevall

Research output: Contribution to journalReview article

21 Scopus citations

Abstract

The field of infectious diseases is in crisis and there is a need for strategies that can facilitate the rapid development of new antimicrobial agents. Radioimmunotherapy (RIT), a therapeutic modality originally developed for cancer treatment, has recently been suggested as a novel therapy for the treatment of a variety of infectious diseases. Because specific antibodies are used in RIT as delivery vehicles of cytocidal radiation, their molecular weight influences the nonspecific accumulation in infectious foci and blood clearance, and their affinity-specific accumulation of antibodies in infectious foci. Like the problems encountered in oncology, relevant variables in the development of RIT of infectious diseases include target antigen-shedding; delivering radionuclides to infectious foci in organs, abscesses, granulomas, heart and brain, and potential safety concerns. Dadachova and Casadevall anticipate that RIT can be developed for many types of infectious diseases, including microbes resistant to conventional antimicrobial therapy and agents of biological warfare.

Original languageEnglish (US)
Pages (from-to)1075-1084
Number of pages10
JournalExpert Opinion on Drug Delivery
Volume2
Issue number6
DOIs
StatePublished - Nov 1 2005

    Fingerprint

Keywords

  • Infectious diseases
  • Monoclonal antibodies
  • Radioimmunotherapy
  • Scintigraphic imaging

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this